SER150 vs Placebo in Diabetic Kidney Disease

Summary

This study is to assess the efficacy and safety of SER150 administered for 24 weeks as a 15 mg twice a day BID dose (except on Day 168 15 mg QD) in participants with type 2 diabetes (T2D) and albuminuria in treatment with either an angiotensin converting enzyme inhibitor (ACEi) or an angiotensin receptor antagonist (ARB).

Timeline

Start

2021-08-18

Primary completion

2024-06-06

Completion

2024-06-06

Drugs

Indications